← Back to Search

Monoclonal Antibodies

Atezolizumab + Bevacizumab for Endometrial Cancer

Phase 2

Waitlist Available

Led By Kathleen Moore, MD

Research Sponsored by University of Oklahoma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Evidence that the endometrial cancer is advanced, recurrent, or persistent and has relapsed or is refractory to curative therapy or established treatments

Patients MSI status must be known (via immunohistochemistry)

Must not have

Initiation of treatment with systemic corticosteroids (either IV or oral steroids, excluding inhalers) within 1 week before administration of the first dose of study drug

Patients with symptomatic, untreated Central nervous system (CNS) metastasis; Patients with a history of treated CNS lesions are eligible if all criteria provided per study protocol are met

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Summary

This trial will test the safety and effectiveness of a combination of two drugs, atezolizumab and bevicacizumab, in women with endometrial cancer that has progressed or come back after treatment.

Who is the study for?

This trial is for women with advanced, recurrent or persistent endometrial cancer who have tried at least one platinum-based chemotherapy but no more than two regimens. Participants must be over 18, understand the study and consent to it, have measurable disease by certain medical imaging standards, an ECOG performance status of 0-2, and agree to use contraception if of childbearing potential.

What is being tested?

The trial is testing a combination of two drugs: Atezolizumab and Bevacizumab in women with specific types of endometrial cancer. It's a Phase II study focusing on the safety and effectiveness (futility) of this drug combo without comparing it to other treatments.

What are the potential side effects?

Potential side effects include allergic reactions related to antibodies or proteins in the drugs; risk of infection; possible nerve damage; gastrointestinal issues like fistula or perforation; bleeding disorders; severe fatigue; and complications from immune system interactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My endometrial cancer is advanced, recurrent, or persistent and does not respond to standard treatments.

Select...

My cancer's MSI status has been tested.

Select...

I have a tumor or lymph node that meets the size requirements for measurement.

Select...

My cancer is a type of endometrial carcinoma.

Select...

I have had 1 or 2 platinum-based treatments for endometrial cancer.

Select...

I can take care of myself and am up and about more than half of my waking hours.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I started taking corticosteroids not more than a week ago.

Select...

I have brain metastases but meet specific treatment criteria.

Select...

I haven't had serious abdominal issues, wounds, or fractures in the last 6 months.

Select...

I have moderate to severe numbness, tingling, or muscle weakness.

Select...

I have been treated with anti-PD-1 or anti-PD-L1 therapy.

Select...

I have an autoimmune disorder like SLE, sarcoidosis, RA, or Crohn's.

Select...

I haven't taken any immune-boosting drugs in the last 6 weeks.

Select...

I haven't had major surgery in the last 28 days and don't expect to need one during the study.

Select...

I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of patients who experience complete or partial tumor response

Secondary study objectives

Number of participants who experience immune related response

Number of patients who experience toxicity

Overall survival

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Bevacizumab + AtezolizumabExperimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bevacizumab

2013

Completed Phase 4

~5540

Atezolizumab

2017

Completed Phase 3

~5850

0 / 15Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor

464 Previous Clinical Trials

91,023 Total Patients Enrolled

6 Trials studying Endometrial Cancer

231 Patients Enrolled for Endometrial Cancer

Genentech, Inc.Industry Sponsor

1,550 Previous Clinical Trials

568,254 Total Patients Enrolled

6 Trials studying Endometrial Cancer

356 Patients Enrolled for Endometrial Cancer

Kathleen Moore, MDPrincipal InvestigatorObstetrics and Gynecology

8 Previous Clinical Trials

335 Total Patients Enrolled

2 Trials studying Endometrial Cancer

88 Patients Enrolled for Endometrial Cancer

Media Library

Atezolizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT03526432 — Phase 2

Endometrial Cancer Research Study Groups: Bevacizumab + Atezolizumab

Endometrial Cancer Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT03526432 — Phase 2

Atezolizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03526432 — Phase 2

~16 spots leftby Sep 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.